Truxima (rituximab), Celltrion’s MabThera biosimilar, became the first oncology monoclonal antibody biosimilar to enter the European market in April 2017. Two months later, Sandoz’s Rixathon, a second MabThera biosimilar, launched in Europe. In this series, we track awareness and uptake of Truxima and Rixathon since launch to understand how their entry will impact the NHL, CLL, and immune biologics market. Along with awareness, familiarity, and perception of Truxima and Rixathon, our analysis looks at the drivers and barriers behind uptake of these agents. Promotional efforts are explored, as well as prescriber and nonprescriber profiles, and benchmarking against other biosimilars, to better understand the dynamics of the German biosimilars market.

Questions Answered:

  • Are German physicians aware of Truxima and Rixathon?
  • What are the drivers to prescribing Truxima and Rixathon? What is the current level of Truxima and Rixathon use, and how is that changing over time?
  • Has experience with Truxima and Rixathon changed physicians’ opinion of biosimilars?
  • Have physicians experienced pressure to prescribe Truxima and Rixathon to patients?
  • What promotional messages are sales representatives employing for Truxima, Rixathon, and MabThera?

Table of contents

  • Biosimilars - Emerging Biosimilars - Oncology & Immunology: Truxima/Rixathon Launch Tracking (Germany) Wave 3
    • Key Findings
      • Biosimilar Prescriber and Nonprescriber Profiles
        • Differences Between Truxima and Rixathon Prescribers and Nonprescribers
        • Truxima: Differences Between Prescriber and Nonprescriber Profiles of Hematology Oncologists
        • Truxima: Differences Between Prescriber and Nonprescriber Profiles of Rheumatologists
        • Rixathon: Differences Between Prescriber and Nonprescriber Profiles of Hematology Oncologists
        • Rixathon: Differences Between Prescriber and Nonprescriber Profiles of Rheumatologists
    • Benchmarking Truxima's and Rixathon's Launch Success vs. Other Biosimilar Launches
      • Launch Metrics of Truxima vs. Rixathon
    • Market Access Analysis
      • Reimbursement of Biosimilars in Germany
        • Biosimilar Pricing
          • List Price for Rituximab
        • Drivers of Biosimilar Uptake
          • German Payers' Opinions on the Market Impact of Biosimilar Rituximab
          • Awareness and Perceptions of Truxima and Rixathon
            • Awareness of and Familiarity with Truxima and Rixathon
              • Unaided Awareness of Drugs for NHL and CLL
              • Unaided Awareness of Drugs for Rheumatoid Arthritis
              • Mean Level of Familiarity with Biosimilars
              • Level of Familiarity with Biosimilars
              • Mean Level of Familiarity with Truxima and Rixathon
              • Level of Familiarity with Truxima and Rixathon
            • Perceptions of Truxima and Rixathon
              • Indications in Which Truxima Is Thought to Have Been Clinically Studied Prior to EC Approval
              • Indications in Which Rixathon Is Thought to Have Been Clinically Studied Prior to EC Approval
              • Indications for Which Physicians Believe Truxima Has EC Approval
              • Indications for Which Physicians Believe Rixathon Has EC Approval
              • Truxima's Clinical Development Profile
              • Indications for Which Physicians Believe Truxima Should Have Been Approved
              • Rixathon's Clinical Development Profile
              • Indications for Which Physicians Believe Rixathon Should Have Been Approved
          • Trial and Use
            • Current Use of Truxima and Rixathon
              • Drugs Prescribed for NHL and CLL
              • Drugs Prescribed for Rheumatoid Arthritis
              • Biosimilars Prescribed
              • Number of Patients Prescribed Truxima and Rixathon
              • Patient Types for Truxima and Rixathon
              • Mean Level of Satisfaction with Truxima
              • Level of Satisfaction with Truxima
              • Mean Level of Satisfaction with Rixathon
              • Level of Satisfaction with Rixathon
              • Current Patient Share in Oncology
              • Current Patient Share in Rheumatoid Arthritis
            • Drivers of and Barriers to Truxima and Rixathon Use
              • Hematology Oncologists' Reasons for Prescribing Truxima and Rixathon
              • Rheumatologists' Reasons for Prescribing Truxima and Rixathon
              • Choosing Between Truxima and Rixathon
              • Reasons for Not Prescribing Truxima
              • Reasons for Not Prescribing Rixathon
              • Factors Encouraging Truxima Use Among Current Nonprescribers
              • Factors Encouraging Rixathon Use Among Current Nonprescribers
              • Percentage of Physicians Unaware of Truxima's Net Cost
              • Truxima's Average Net Cost vs. That of MabThera
              • Percentage of Physicians Unaware of Rixathon's Net Cost
              • Rixathon's Average Net Cost vs. That of MabThera
              • Prescriber Perception of Truxima's and Rixathon's Similarity to MabThera
              • Anticipated Time to Start Prescribing Truxima
              • Anticipated Time to Start Prescribing Rixathon
          • External Factors Affecting Use
            • Sources of Pressure or Recommendations to Use Rixathon and Truxima
              • Recommendations to Hematology Oncologists for Use of Biosimilar Rituximab
              • Recommendations to Rheumatologists for Use of Biosimilar Rituximab
              • Encouragement and Expectations to Meet Prescribing Quota for Rituximab Biosimilars
              • Mean Reported Prescribing Quota for Rituximab Biosimilars
              • Expectations for the Creation of a Reference-Pricing Group
            • Patients' Acceptance of Truxima and Rixathon
              • Patients' Acceptance of Truxima and Rixathon Following Proposal by Their Physician
              • Percentage of Surveyed Physicians Who Have Not Proposed Using Truxima or Rixathon to Their Patients
          • Promotional Activity
            • Promotional Activity for Truxima and Rixathon
              • Timing of Sales Representatives' Last Contact
              • Topics Discussed by Sales Representatives to Hematology Oncologists
              • Topics Discussed by Sales Representatives to Rheumatologists
          • Future Use of Biosimilars
            • Willingness to Prescribe Novel Biosimilars
              • Physicians' Likelihood of Prescribing Other Novel Biosimilars Based on Experience with Truxima or Rixathon
              • Mean Likelihood of Prescribing a Novel Rituximab Biosimilar
              • Hematology Oncologists' Likelihood of Prescribing a Novel Rituximab Biosimilar
              • Rheumatologists' Likelihood of Prescribing a Novel Rituximab Biosimilar
            • Future Patient Share Expectations for Truxima and Rixathon
              • Rituximab Biosimilar Patient Share in Oncology in Five Years
              • Rituximab Biosimilar Patient Share in Rheumatoid Arthritis in Five Years
          • Appendix
            • Background on the German Rituximab Market
              • Background on Truxima's Development and Marketing
              • Timeline of EU Milestones for Truxima
              • The Celltrion Partnership Network
              • Background on Rixathon's Development and Marketing
              • Timeline of EU Milestones for Rixathon
              • Current and Future Biosimilar Landscape
              • Timeline of EU Approvals of Other Oncology and Immunology Biosimilars
              • Novel Rituximab Biosimilars in Late-Phase Development
            • Market News
              • Methodology and Objectives
                • Objectives
                • Physician Research Methodology
                • Number of Study Participants
                • Significance Testing in This Study
                • Payer Research Methodology
              • Respondent Demographics
                • Mean Number of Years in Clinical Practice
                • Practice Type
                • Regional Prescribing Associations in Which Respondents Conduct the Majority of Their Prescribing
                • Number of Oncology Patients Under Management
                • Number of Rheumatoid Arthritis Patients Under Management
              • Abbreviations
                • Table of Abbreviations

          Author(s): Hamzah Aideed, M.Sc.

          Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology.

          Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an M.Sc. in Biotechnology & Business Management from the University of Warwick and a B.Sc. in Biological Chemistry from Aston University.

           


          Related Reports

          Biosimilars - Market Events And Forecast - Oncology

          In 2019, sales of branded monoclonal antibody biologics in oncology exceeded $18 billion across the major markets (United States, EU5, and Jap...

          View Details

          Biomarkers In Oncology - Access & Reimbursement - Detailed, Expanded Analysis (US) Biomarkers In Oncology

          Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malig...

          View Details

          Biosimilars - Geographic Focus: China - Biosimilars | China In-Depth | Oncology And Immunology | China

          The approval of Shanghai Henlius Biotech's HLX01—a biosimilar of Roche's Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then, b...

          View Details

          Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 2

          Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the seco...

          View Details